Background Medical therapy gives excellent short-term outcomes for patients with Stanford type B acute aortic dissection. However, the affected aorta is often compromised by aneurysmal dilatation and rupture, resulting in poor long-term outcome. The present study investigated which antihypertensive treatment may prevent longterm aortic events in these patients.
revious studies have indicated that medical therapy provides an excellent outcome for patients with uncomplicated Stanford type B acute aortic dissection. In fact, the 30-day survival rate of patients receiving medical treatment is as high as 92%. 1 However, the affected aorta is often compromised by aneurysmal dilatation and rupture during the chronic phase, which may result in poor long-term outcome. We have previously reported that dissection-related deaths occurred in the first 2 years of followup in 13.6% of patients with acute type B aortic dissection receiving medical treatment, and in the first 5 years in 29% of patients. 2 Similarly, other studies indicated that 20-40% of patients who had survived the acute phase with antiimpulse therapy eventually underwent surgical treatment during follow-up. [3] [4] [5] [6] [7] [8] [9] To improve the long-term outcome of patients with type B aortic dissection, medical therapy should be further optimized.
To data, however, limited data are available regarding the optimal long-term medical therapy for these patients. Angiotensin-converting enzyme inhibitors (ACEI) appear to prevent aortic expansion and rupture in animal models of aortic aneurysm. 10 In addition, ACEIs have been associated with a reduced risk of abdominal aortic aneurysm rupture in humans. 11 Such protective effects are not apparent for other antihypertensive drugs, including angiotensin II type 1 receptor blockers (ARB) and calcium-channel blockers (CCB). Accordingly, we performed a retrospective analysis to investigate the hypothesis that the use of ACEI may reduce the long-term adverse aortic events in patients with medically-treated Stanford type B aortic dissection.
Methods

Study Patients
Between December 2000 and January 2006, a total of 383 patients with acute aortic dissection (138 with Stanford type A, 245 with Stanford type B) were admitted to the Cardiology Department of the National Cardiovascular Center, Suita, Japan. Of them, 78 patients were admitted within 48 h of the onset of type B aortic dissection and treated with conservative medical therapy. Patients who were judged at initial presentation as candidates for emergency aortic surgery or endovascular intervention, those who had prior episodes of aortic dissection and/or aortic surgery, those with Marfan syndrome, and those with uncontrolled systemic diseases including malignancy, were excluded.
The diagnosis of Stanford type B acute aortic dissection was confirmed by computed tomography (CT) scanning or magnetic resonance imaging (MRI) performed at the time of admission. Follow-up CT scanning or MRI was routinely performed at the prescribed intervals (ie, at 1 week, 2 weeks, 1 month, 3 months, 6 months, 1 year, and every year thereafter). During the acute phase, all patients were initial-ly treated with anti-impulse therapy if there were no indications for surgical treatment such as aortic rupture, diameter of the descending aorta ≥60 mm, malperfusion of thoracoabdominal aorta, and pseudocoarctation syndrome with uncontrollable hypertension.
Data Collection
All patients who survived the acute phase with medical therapy and were discharged from the hospital were followed-up in the outpatient clinic. The baseline clinical characteristics, such as smoking habit, comorbidities including hypertension, diabetes mellitus, dyslipidemia, patency of the false lumen, the diameter of the dissected aorta, and presence of true aortic aneurysm, were evaluated using hospital records under the auspices of the institutional cardiovascular outcomes monitoring program. Patients' outcomes were assessed on the basis of dissection-related aortic events, which included aortic rupture/impending rupture, recurrence of dissection, aortic expansion ≥60 mm, rapid expansion of dissected aorta at a rate ≥10 mm/year, and development of visceral or limb ischemia.
Statistical Analyses
SPSS software version 11.0 (Chicago, IL, USA) was used for all statistical analyses. Continuous variables are expressed as mean ± standard deviation (SD). Statistical significance was evaluated using unpaired Student's t-test for comparisons between 2 means, and a chi-square test for categorical data. Event-free survival was estimated using the Kaplan-Meier survival method with log-rank statistics. Survival time was defined as the interval between the onset of dissection and the time of the aortic event. Cox proportional hazard models were used to identify predictors of aortic events. All the variables included in the final model satisfied hazard assumption. A p-value <0.05 was considered statistically significant.
Results
Dissection-Related Aortic Events
Of the 78 patients, (94%) 73 survived the acute phase and were discharged from hospital with medical therapy including -blockers, CCB, ACEI, ARB, -blocker, and thiazide diuretics. During the average follow-up of 878± 548 days, dissection-related aortic events were observed in 13 of 73 (18%) hospital survivors of medically-treated type B aortic dissection (Table 1) . Dissection-related aortic events included aortic rupture in 2 (3%) patients, enlargement of dissected aorta of ≥60 mm in 7 (10%) patients, rapid enlargement of the dissected aorta in 3 (4 %) patients, and visceral/limb ischemia in 1 (1%) patient.
Antihypertensive Drugs and Dissection-Related Aortic Events
At hospital discharge, 65 of the 73 (89%) patients received -blocker, 63 (86%) CCB, 34 (47%) ACEI, 21 (29%) ARB, 20 (27%) -blocker, and 6 (8%) thiazide diuretics. Patients receiving ACEI had a significantly lower incidence of dissection-related aortic events than those not receiving ACEI (6% vs 28%, p=0.02). However, other antihypertensive drugs showed no significant association with the incidence of dissection-related aortic events (Tables 1,2) . (Table 3 ). Univariate analyses revealed that patients with ACEI were significantly younger than those without (67±10 years vs 73±10 years, p=0.04); and were less frequently prescribed ARB (12% vs 44%, p=0.003).
Protective Association Between ACEI and DissectionRelated Aortic Events
Multivariate analyses were carried out to examine the protective effect on aortic events associated with the use of ACEI (Table 4) . Variables examined were age, and the use of ARB, ACEI, and -blocker. Age and ARB were included because they were shown to be related to the use of ACEI by univariate analysis. The use of -blocker was not associated with aortic events by univariate analysis, but was included in the multivariate analysis because the use ofblockers was suggested in a previous study to have a protective effect on dissection-related aortic events. 12 The results of multivariate analysis revealed that only the use of ACEI had a significant protective association with dissection-related aortic events (p=0.03, odds ratio: 0.18, 95% confidence interval: 0.04-0.85) and that -blockers tended towards significant, but was not at an level of 0.05 (p=0.06).
Dissection-related aortic-events-free survival curves are shown in Fig 1. All events occurred within 3 years. The 1-and 3-year cumulative event-free rates of patients receiving ACEI and those not receiving ACEI were, respectively, 97% vs 77% at 1 year; and 92% vs 64% at 3 year. The dissection-related aortic events-free survival rate was significantly higher in patients treated with ACEI than in those not treated with ACEI (p=0.01). 
Discussion
In patients with uncomplicated Stanford type B acute aortic dissection, medical therapy provides an excellent short-term outcome, with a 30-day survival rate as high as 92%; 1 however, aortic events such as rupture, recurrent dissection, and aneurysmal dilatation often compromise the long-term outcome of these patients. Previous studies indicate that up to 40% of patients who survive the acute phase with medical therapy eventually experience aortic events. [3] [4] [5] [6] [7] Other studies also indicate that 13-32% of patients with acute type B aortic dissection require surgical treatment during follow-up. 5, 6, 13 Similarly, in the current study, dissection-related aortic events occurred in 18% of hospital survivors during an average of 2.4 years of follow-up. Such a high incidence of aortic events and necessity of surgical repair underscore the importance of optimizing the medical treatment for the chronic stage of type B aortic dissection.
In this study, we documented that treatment with ACEI was associated with a significantly reduced risk of dissection-related aortic events in patients who survived the acute phase. This association was maintained after adjustment for measured confounders. Moreover, the relationship between ACEI and aortic events was distinct and was not apparent for ARB treatment.
The precise mechanisms whereby ACEI prevented dissection-related aortic events were not investigated in the current study. In this regard, Hackam et al proposed several possible biological pathways in patients with abdominal aortic aneurysm. 11 First, administration of angiotensin II to hyperlipidemic mice increases aortic stiffness by 900%, reduces elastin content by 74%, and induces the formation of aortic dilatation. 14 The use of ACEI, but not other antihypertensive agents, augments systemic collagen synthesis and reduces stiffness of the aortic wall. 15 Second, augmentation index and pulse wave velocity decrease with ACEI treatment, and arterial compliance improves. 16 Third, ACEI reduces vascular inflammation, increases elastin and fibrillin deposition, and inhibits matrix metalloproteinases. 16, 17 The -blockers have been shown to reduce the progression of aortic dilatation and the incidence of subsequent hospital admission, as well as the incidence of late dissection-related aortic procedures and the cost of treatment in patients with chronic type B aortic dissection. 12 Such benefits of -blockers are considered to derive from their impact on blood pressure and the negative inotropic and chronotropic effects. In the current study, we observed only marginal benefit for -blockers as a long-term outcome, which may be explained by the fact that -blockers were administered to nearly 90% of the study patients. Such a high prevalence of -blocker usage might have made the power of the statistical analyses inadequate to assess the impact of -blockers exclusively.
Study Limitations
First, the results of the current study are based on a retrospective and nonrandomized analysis. Second, the mechanisms for the differences in the impact upon long-term aortic event between ACEI and ARB remain unknown. Finally, most of the study patients received multiple antihypertensive agents. Therefore, it remains unknown whether the benefit of ACEI observed in the current study was independent of its antihypertensive effect. Subsequent prospective study will be required to clarify these issues.
Conclusions
Use of ACEI was associated with a reduced risk of longterm aortic events in patients with type B aortic dissection in the present study, suggesting that patients who survive the acute phase of aortic dissection may benefit from this treatment. Whether ACEI treatment in fact improves longterm outcome awaits further investigation.
